Results 91 to 100 of about 13,138,637 (305)

Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology

Molecular Oncology, EarlyView.
This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic, Maria Concetta Vitale, Rita Siino, Emilia Di Giovanni, Carla Ferrante Bannera, Enrico Di Marco, Andrea Gottardo, Tancredi Didier Bazan Russo, Nadia Barraco, Alessandro Perez, Valerio Gristina, Antonio Galvano, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan, Lorena Incorvaia   +15 more
wiley   +1 more source

Growth Hormone-Releasing Hormone Antagonists Inhibit Growth of Human Ovarian Cancer

, 2011
Epithelial ovarian carcinoma is the leading cause of cancer-related deaths among women with gynecologic malignancies. Antagonists of the growth hormone-releasing hormone (GHRH) have been shown to inhibit growth of various cancers through endocrine ...
A. Papadia, Rick, F, Szalontay, L, Buchholz, S, L. Szalontay, G. Halmos, Papadia, A, F. Rick, Lucci, J. A, M. Zarandi, Bellyei, S, A. Schally, S. Bellyei, S Seitz, J. Lucci, Zarandi, M, S. Buchholz, Halmos, G, Varga, J. L, Treszl, A, A. Treszl, Schally, A. V, Seitz, S, J. Varga   +23 more
core   +1 more source

Thyrotropin-releasing hormone (TRH) promotes wound re-epithelialisation in frog and human skin [PDF]

, 2013
There remains a critical need for new therapeutics that promote wound healing in patients suffering from chronic skin wounds. This is, in part, due to a shortage of simple, physiologically and clinically relevant test systems for investigating candidate ...
Paredes Roberto, Matthias Augustin, Jennifer E Kloepper, Amaya, Enrique; id_orcid, Roberto Paredes (452874), Pattwell David M., Natalia T. Meier (452870), Enrique Amaya, Matthias Augustin (452876), Haslam Iain S., Augustin Matthias, Paus Ralf, Hardman, Matthew J, Kloepper, Jennifer E, Paus, Ralf, Sebastian Debus, Pattwell, David M., Wolfgang Funk, Matthew J Hardman, Wolfgang Funk (405807), Kloepper Jennifer E., Meier Natalia T., Matthew J. Hardman (452878), Amaya, Enrique, Zhang, Guo You, Amaya Enrique, Debus, Sebastian, Zhang Guo-You, Vladimir Emelianov (452873), Jennifer E. Kloepper (452877), Paredes, Roberto, Emelianov Vladimir, Guo-You Zhang, Sebastian Debus (452875), Hardman Matthew J., Haslam, Iain S., Funk Wolfgang, Hardman, Matthew J., Augustin, Matthias, Pattwell, David M, Kloepper, Jennifer E., Haslam, Iain S, Enrique Amaya (31703), Ralf Paus (261703), Emelianov, Vladimir, Haslam, Iain, Zhang, Guo-You, Natalia T Meier, Debus Sebastian, Meier, Natalia T., Vladimir Emelianov, Iain S Haslam, Roberto Paredes, David M. Pattwell (452872), Ralf Paus, Meier, Natalia T, Guo-You Zhang (397743), Funk, Wolfgang, Iain S. Haslam (452871), David M Pattwell   +59 more
core   +2 more sources

Changes in ghrelin and nesfatin-1 in children with growth hormone deficiency treated by recombinant human growth hormone

European Journal of Inflammation, 2019
This study aims to investigate the effects of recombinant human growth hormone (rhGH) on serum nesfatin-1 and ghrelin in children with growth hormone deficiency (GHD), in order to provide a reliable basis for the effectiveness and safety of applying rhGH
Yu Wang, Meng Sun, Xin Wang, Ya-Ying Cheng   +3 more
doaj   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Comparison between short- and long-term insulin-like growth factor response to recombinant human growth hormone

, 1992
Eight growth-hormone-deficient children were treated with recombinant human GH (rhGH). Results of the short-term metabolic response to rhGH performed at the start of therapy during a 5-day introduction period and long-term results on growth were analyzed.
Lopes, L. A., Theintz, G. E., Sizonenko, P. C., Torresani, T.   +3 more
core  

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency

, 2011
Objective: The goal of growth hormone (GH) replacement is to improve quality of life (QoL) and prevent the long-term complications of GH deficiency (GHD).
Ueland, T., Schreiner, T., A.P. Jørgensen, K.J. Fougner, Fougner, K. J., Bollerslev, J., T. Schreiner, J. Bollerslev, Burman, Pia, Gudmundsen, O., P. Burman, Jorgensen, A. P., T. Ueland, O. Gudmundsen, Burman, Pia,, Lund University.   +15 more
core   +1 more source

Iatrogenic Creutzfeldt-Jakob Disease, Final Assessment

Emerging Infectious Diseases, 2012
The era of iatrogenic Creutzfeldt-Jakob disease (CJD) has nearly closed; only occasional cases with exceptionally long incubation periods are still appearing.
Paul Brown, Jean-Philippe Brandel, Takeshi Sato, Yosikazu Nakamura, Jan MacKenzie, Robert G. Will, Anna Ladogana, Maurizio Pocchiari, Ellen W. Leschek, Lawrence B. Schonberger   +9 more
doaj   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source